

CONTENTS

<i>Contributors</i>	<i>xiii</i>
<i>Preface</i>	<i>xxi</i>
<i>Volumes in Series</i>	<i>xxiii</i>

Section I. Tools 1

1. Designing a Diverse High-Quality Library for Crystallography-Based FBDD Screening 3

Brett A. Tounge and Michael H. Parker

1. Introduction	4
2. Library Requirements for Different Screening Methods	6
3. Library Design for X-Ray Screening	8
4. Implementation	13
5. Conclusions	17
References	19

2. Preparation of Protein Samples for NMR Structure, Function, and Small-Molecule Screening Studies 21

Thomas B. Acton, Rong Xiao, Stephen Anderson, James Aramini, William A. Buchwald, Colleen Ciccocanti, Ken Conover, John Everett, Keith Hamilton, Yuanpeng Janet Huang, Haleema Janjua, Gregory Kornhaber, Jessica Lau, Dong Yup Lee, Gaohua Liu, Melissa Maglaqui, Lichung Ma, Lei Mao, Dayaban Patel, Paolo Rossi, Seema Sahdev, Ritu Shastry, G. V. T. Swapna, Yeufeng Tang, Saichiu Tong, Dongyan Wang, Huang Wang, Li Zhao, and Gaetano T. Montelione

1. Introduction	23
2. Bioinformatics Infrastructure and Target Curation	24
3. Ligation-Independent High-Throughput Cloning and Analytical Scale-Expression Screening	29
4. Midi-Scale Protein Expression and Purification	38
5. Preparative-Scale Fermentation	45
6. Preparative-Scale Purification	47
7. Salvage Strategies	49
8. <i>E. coli</i> Single Protein Production System for Isotopic Enrichment	55

9. Conclusions	56
Acknowledgments	57
References	57
3. Key Factors for Successful Generation of Protein-Fragment Structures: Requirement on Protein, Crystals, and Technology	61
Jark Böttcher, Anja Jestel, Reiner Kiefersauer, Stephan Krapp, Susanna Nagel, Stefan Steinbacher, and Holger Steuber	
1. Introduction	62
2. General Target Properties and Protein Sources in Protein-Fragment Crystallography	63
3. Fragment Properties and the Crystallization Setup	66
4. Quality of Crystallographic Data	76
5. Application of the Free Mounting System and the Picodropper Technology to Improve Ligand Occupancy	78
6. Conclusions	82
Acknowledgments	82
References	82
4. Predicting the Success of Fragment Screening by X-Ray Crystallography	91
Douglas R. Davies, Darren W. Begley, Robert C. Hartley, Bart L. Staker, and Lance J. Stewart	
1. Introduction	92
2. Fragment Screening and Druggability	93
3. Fragment Screening Campaigns in This Review	95
4. Crystallization Conditions of Fragment Targets	98
5. Solvent Content and Solvent Channels	99
6. Pocket Predictions for Fragment Screening Targets	101
7. Summary	110
Acknowledgments	111
References	111
5. Fragment Screening of Stabilized G-Protein-Coupled Receptors Using Biophysical Methods	115
Miles Congreve, Rebecca L. Rich, David G. Myszk, Francis Figaroa, Gregg Siegal, and Fiona H. Marshall	
1. Introduction	116
2. Case Study 1: Biacore Fragment Screen of Adenosine A _{2A} StaR	117
3. Case Study 2: TINS NMR Fragment Screen of β_1 -Adrenergic StaR	124

4. Discussion	133
Acknowledgments	135
References	135
6. Using Computational Techniques in Fragment-Based Drug Discovery	137
Renee L. Desjarlais	
1. Introduction	138
2. Fragment Library Design	139
3. <i>In Silico</i> Fragment Screening	143
4. Hit Triage	148
5. Hit Follow-Up	150
6. Iteration	152
7. Conclusion	152
References	153
Section II. Practical Approaches	157
7. How to Avoid Rediscovering the Known	159
Lawrence C. Kuo	
1. Why FBDD?	160
2. Types of Screen	161
3. Size of a Fragment	162
4. Choice of Fragments	163
5. Fragment Progression	165
6. Conclusion	166
References	167
8. From Experimental Design to Validated Hits: A Comprehensive Walk-Through of Fragment Lead Identification Using Surface Plasmon Resonance	169
Anthony M. Giannetti	
1. Introduction: Biophysical Principles of Surface Plasmon Resonance	170
2. Preparing the Instrument	172
3. Surface Preparation	174
4. Target Immobilization	174
5. Buffer and Compound Preparation	181
6. Assay Development	183
7. Aligning the SPR Assay with Crystallography	186
8. Pilot Screening	187
9. Setting Up the Fragment Screen	187

10. Executing the Screen	197
11. Primary Screen Data Reduction	199
12. Data Quality Control and Extraction of the Equilibrium Binding Level	200
13. Scaling and Normalization of Primary Screening Data	202
14. Primary Screen Active Selection	205
15. Collecting Dose-Response Hit Confirmation Data	206
16. Dose-Response Data Reduction and Quality Control	208
17. Global Analysis for K_D Determination	209
18. Conclusion	216
Acknowledgments	216
References	217
9. Practical Aspects of NMR-Based Fragment Screening	219
Christopher A. Lepre	
1. Introduction	220
2. Constructing the Fragment Library	221
3. Developing the Screen	227
4. After the Screen	232
5. Conclusions	235
Acknowledgments	236
References	236
10. Binding Site Identification and Structure Determination of Protein-Ligand Complexes by NMR: A Semiautomated Approach	241
Joshua J. Ziarek, Francis C. Peterson, Betsy L. Lytle, and Brian F. Volkman	
1. Introduction	242
2. Automated and Semiautomated Chemical Shift Assignment	243
3. Identification of Ligand Binding Sites by Chemical Shift Mapping	250
4. 3D Structure Determination by NMR	258
5. Conclusion	268
References	268
11. Protein Thermal Shifts to Identify Low Molecular Weight Fragments	277
James K. Kranz and Celine Schalk-Hihi	
1. Introduction	278
2. Thermal Shift Assays	279
3. Binding Affinity in Thermal Shifts	282
4. Typical Thermal Shift Assay Development	289

5. Dynamic Range of Thermal Shift Assays and Guidelines For a "Significant" Binding Event	293
Acknowledgment	296
References	296
12. HTS Reporter Displacement Assay for Fragment Screening and Fragment Evolution Toward Leads with Optimized Binding Kinetics, Binding Selectivity, and Thermodynamic Signature	299
Lars Neumann, Konstanze von König, and Dirk Ullmann	
1. Introduction	300
2. The Reporter Displacement Assay	301
3. Residence Time and Kinetic Selectivity in Fragment Evolution	305
4. High-Throughput Thermodynamics in Fragment Evolution	311
5. Conclusion	319
Acknowledgments	319
References	319
13. Fragment Screening Purely with Protein Crystallography	321
John C. Spurlino	
1. Introduction	322
2. The Primary Library Screen	329
3. The Secondary Library Screen	348
4. Why Screening Purely with X-Ray Structures Works	353
Acknowledgments	354
References	354
14. Computational Approach to <i>De Novo</i> Discovery of Fragment Binding for Novel Protein States	357
Zenon D. Konteatis, Anthony E. Klon, Jinming Zou, and Siavash Meshkat	
1. Introduction	358
2. Protein Modeling	359
3. Fragment Binding in Protein Model: Methods for Free Energy Calculation	363
4. Protein Binding Site Characterization Via Fragment Simulations	368
5. Fragment-Based Design	375
6. Future Directions	376
Acknowledgments	379
References	379

Section III. Examples	381
15. Lead Generation and Examples: Opinion Regarding How to Follow Up Hits	383
Masaya Orita, Kazuki Ohno, Masaichi Warizaya, Yasushi Amano, and Tatsuya Niimi	
1. Introduction	384
2. Ligand Efficiency	386
3. Four Different Approaches for Converting Fragment Hits to Leads	391
4. Following Up on Hits: Anchor-Based Drug Discovery	398
5. Conclusions	416
References	417
16. Medicinal Chemistry Inspired Fragment-Based Drug Discovery	421
James Lanter, Xuqing Zhang, and Zhihua Sui	
1. Introduction	422
2. Medicinal Chemistry Engagement in Fragment-Based Drug Design	427
3. Case Studies—MACS2b and Kethexokinase	429
4. Conclusion	444
Acknowledgment	444
References	444
17. Effective Progression of Nuclear Magnetic Resonance-Detected Fragment Hits	447
Hugh L. Eaton and Daniel F. Wyss	
1. Introduction	448
2. How to Plan for a Successful NMR-Based FBDD Campaign?	448
3. How to Prioritize NMR-Detected Fragment Hits for Lead Generation?	455
4. How to Progress NMR-Detected Fragment Hits into Leads?	457
5. In-house Example of a Successful FBDD Campaign	458
Acknowledgments	466
References	466
18. Advancing Fragment Binders to Lead-Like Compounds Using Ligand and Protein-Based NMR Spectroscopy	469
Till Maurer	
1. Introduction	470
2. Strategies for Defining Hits	471

3. The Fragment Library and Protein Production	472
4. NMR Follow-Up and Fragment Hit-To-Lead	473
5. Characterizing Binding Modes and Co-Structure Information through Docking	476
6. The Process in an Example	477
7. Summary and Conclusions	484
Acknowledgment	484
References	484
19. Electron Density Guided Fragment-Based Drug Design—A Lead Generation Example	487
Marta C. Abad, Alan C. Gibbs, and Xuqing Zhang	
1. Introduction	488
2. Electron Density Guided FBDD	488
3. Ketohexokinase	491
4. Ketohexokinase FBDD	493
5. First View of the Solution Activity of the Arylamide Lead	506
Acknowledgments	506
References	507
20. Experiences in Fragment-Based Lead Discovery	509
Roderick E. Hubbard and James B. Murray	
1. Introduction	510
2. Maintaining and Enhancing a Fragment Library	512
3. Issues with Different Methods for Fragment Screening	513
4. Hit Rates for Different Classes of Target	521
5. Success Stories in Fragment Evolution	523
6. Thoughts on How to Decide Which Fragments to Evolve	526
7. Final Comments	528
Acknowledgments	529
References	529
21. Fragment Screening of Infectious Disease Targets in a Structural Genomics Environment	533
Darren W. Begley, Douglas R. Davies, Robert C. Hartley, Thomas E. Edwards, Bart L. Staker, Wesley C. Van Voorhis, Peter J. Myler, and Lance J. Stewart	
1. Introduction	534
2. Methods	538

3. Case Studies	543
4. Conclusions	549
Acknowledgments	550
References	550
<i>Author Index</i>	557
<i>Subject Index</i>	579